Overview
- Repertoire receives $85 million upfront plus up to $1.84 billion in development and commercial milestones, with tiered royalties on sales.
- The biotech will use its DECODE T-cell receptor–epitope discovery platform to generate up to three autoimmune candidates before handoff to Lilly.
- Lilly will lead clinical development, manufacturing, regulatory activities, and commercialization of any selected therapies.
- The partners say they aim for treatments that restore immune balance and deliver durable remission without broad immune suppression.
- Specific disease targets were not disclosed, as Lilly expands its immunology footprint and Repertoire advances a partnership-focused strategy that includes Genentech, Bristol Myers Squibb, and Pfizer.